K-V Complaint Over Compound Medicine Rejected by U.S. ITC

K-V Pharmaceutical Co. (KVPHQ) , a bankrupt maker of women’s health-care products, lost its bid to use a U.S. trade agency to keep competitors from importing versions of a medicine that prevents premature births, after federal drug regulators had refused to stop them.

Excerpt from:

K-V Complaint Over Compound Medicine Rejected by U.S. ITC

Related Posts

Comments are closed.